Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Org 25935 Augmentation of CBT in Panic Disorder
NCT00725725Phase 2Terminated
- Sponsor
- Merck & Co.
- Start
- Jul 2008
- Primary completion
- Apr 2010
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of org 25935 in panic disorder, sponsored by Merck & Co.. Started Jul 2008; status: terminated.
02
Drugs
org 25935
03
Conditions
panic disorder
Beyond the preview
Go deeper on NCT00725725.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00725725.